LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives Consensus Rating of “Buy” from Brokerages

LENZ Therapeutics, Inc. (NASDAQ:LENZ) has been given a consensus rating of “Buy” by the six research firms that are presently covering the company, MarketBeat reports. Five analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $35.00.

LENZ has been the subject of a number of research analyst reports. HC Wainwright assumed coverage on LENZ Therapeutics in a research note on Monday, August 12th. They issued a “buy” rating and a $38.00 target price for the company. Piper Sandler reiterated an “overweight” rating and set a $36.00 price target on shares of LENZ Therapeutics in a research note on Thursday, August 15th. Finally, William Blair raised LENZ Therapeutics to a “strong-buy” rating in a report on Friday, August 30th.

Institutional Trading of LENZ Therapeutics

A number of institutional investors have recently bought and sold shares of LENZ. American International Group Inc. bought a new stake in LENZ Therapeutics during the first quarter worth about $44,000. Marquette Asset Management LLC purchased a new position in LENZ Therapeutics in the first quarter valued at about $131,000. Squarepoint Ops LLC purchased a new stake in LENZ Therapeutics during the second quarter valued at approximately $181,000. Rhumbline Advisers raised its stake in LENZ Therapeutics by 265.6% in the 2nd quarter. Rhumbline Advisers now owns 16,812 shares of the company’s stock worth $291,000 after acquiring an additional 12,214 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its stake in LENZ Therapeutics by 28.4% during the 2nd quarter. Renaissance Technologies LLC now owns 60,166 shares of the company’s stock valued at $1,040,000 after acquiring an additional 13,300 shares during the period. 54.32% of the stock is currently owned by institutional investors.

LENZ Therapeutics Stock Down 1.0 %

Shares of NASDAQ:LENZ opened at $23.94 on Friday. LENZ Therapeutics has a 52-week low of $14.07 and a 52-week high of $29.82. The stock has a fifty day moving average of $22.40.

LENZ Therapeutics (NASDAQ:LENZ) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.09. Sell-side analysts predict that LENZ Therapeutics will post -2.81 EPS for the current year.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.